`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`ELI LILLY AND COMPANY
`Petitioner
`v.
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner
`______________________
`
`IPR2018-01425
`Patent No. 9,890,210
`______________________
`
`PETITIONER’S UPDATED EXHIBIT LIST AS OF SEPTEMBER 10, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`Further to 37 C.F.R. § 42.63(e), Petitioner Eli Lilly and Company hereby
`
`IPR2018-01425
`Patent No. 9,890,210
`
`submits a current listing of Lilly Exhibits.
`
`Exhibit
`
`Description
`
`Ex. 1001
`
`U.S. Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`
`Ex. 1002
`
`Reserved
`
`Ex. 1003
`
`Reserved
`
`Ex. 1004
`
`Reserved
`
`Ex. 1005
`
`Reserved
`
`Ex. 1006
`
`Reserved
`
`Ex. 1007
`
`Reserved
`
`Ex. 1008
`
`Reserved
`
`Ex. 1009
`
`Reserved
`
`Ex. 1010
`
`Ex. 1011
`
`Declaration of Andrew Charles, M.D. (U.S. Patent No.
`9,890,210)
`
`Declaration of Alain P. Vasserot (U.S. Patent No.
`9,890,210)
`
`Ex. 1012
`
`Reserved
`
`Ex. 1013
`
`Reserved
`
`Ex. 1014
`
`Reserved
`
`Ex. 1015
`
`Reserved
`
`Ex. 1016
`
`Reserved
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1017
`
`Reserved
`
`Ex. 1018
`
`Reserved
`
`Ex. 1019
`
`Teva’s U.S. Provisional Application No. 60/736,623
`
`Ex. 1020
`
`Teva’s PCT Application No. WO 2007/054809
`
`Ex. 1021
`
`Ex. 1022
`
`Tan et al., “Demonstration of the Neurotransmitter Role of
`Calcitonin Gene-Related Peptides (CGRP) by
`Immunoblockade with Anti-CGRP Monoclonal
`Antibodies,” Br. J. Pharmacol. (1994) 111: 703-710
`
`Tan et al., “Calcitonin Gene-Related Peptide as an
`Endogenous Vasodilator: Immunoblockade Studies in vivo
`with an Anti-Calcitonin Gene-Related Peptide Monoclonal
`Antibody and Its Fab’ Fragment,” Clinical Sci. (1995) 89:
`565-573
`
`Ex. 1023
`
`Queen et al., U.S. Patent No. 6,180,370
`
`Ex. 1024
`
`Ex. 1025
`
`Doods et al., “Pharmacological Profile of BIBN4096BS,
`the First Selective Small Molecule CGRP Antagonist,” Br.
`J. Pharmacol. (2000) 129: 420-423
`
`Olesen et al., “Calcitonin Gene-Related Peptide Receptor
`Antagonist BIBN 4096 BS for the Acute Treatment of
`Migraine,” N. Engl. J. Med. (2004) 350: 1104-1110
`
`Ex. 1026
`
`Sveinsson, International Publication No. WO 2004/014351
`
`Ex. 1027
`
`Salmon et al., U.S. Patent Application Publication No. US
`2002/0162125
`
`Ex. 1028
`
`De Lacharriere et al., U.S. Patent No. 6,344,438
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1029
`
`Ex. 1030
`
`Ex. 1031
`
`Olesen et al., “S26 CGRP Antagonism as a New
`Therapeutic Principle in Acute Migraine,” Neuropeptides
`(2004) 38: 110-131
`
`Arndt et al., “CGRP Antagonism — A Valid New Concept
`for the Treatment of Migraine Pain,” Neuropeptides (2004)
`38: 110-131
`
`Arulmani et al., “Calcitonin Gene-related Peptide and Its
`Role in Migraine Pathophysiology,” Eur. J. Pharmacol.
`(2004) 143: 315-330
`
`Ex. 1031A Arulmani et al., “Calcitonin Gene-related Peptide and Its
`Role in Migraine Pathophysiology,” Eur. J. Pharmacol.
`(2004) 143: 315-330
`
`Ex. 1032
`
`Frobert et al., “A Sensitive Sandwich Enzyme
`Immunoassay for Calcitonin Gene-Related Peptide
`(CGRP): Characterization and Application,” Peptides
`(1999) 20: 275-284
`
`Ex. 1032A Frobert et al., “A Sensitive Sandwich Enzyme
`Immunoassay for Calcitonin Gene-Related Peptide
`(CGRP): Characterization and Application,” Peptides
`(1999) 20: 275-284
`
`Ex. 1033 Wong et al., “Monoclonal Antibody to Rat α-CGRP:
`Production, Characterization, and in vivo
`Immunoneutralization Activity,” Hybridoma (1993) 12: 93-
`106
`
`Ex. 1033A Wong et al., “Monoclonal Antibody to Rat α-CGRP:
`Production, Characterization, and in vivo
`Immunoneutralization Activity,” Hybridoma (1993) 12: 93-
`106
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`3
`
`
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Exhibit
`
`Ex. 1034
`
`Rist et al., “From Micromolar to Nanomolar Affinity: A
`Systematic Approach to Identify the Binding Site of CGRP
`at the Human Calcitonin Gene-Related Peptide 1
`Receptor,” J. Med. Chem. (1998) 41: 117-123
`
`Ex. 1034A Rist et al., “From Micromolar to Nanomolar Affinity: A
`Systematic Approach to Identify the Binding Site of CGRP
`at the Human Calcitonin Gene-Related Peptide 1
`Receptor,” J. Med. Chem. (1998) 41: 117-123
`
`Ex. 1035
`
`Edvinsson and Hargreaves, The Headaches 289-299 (3rd
`ed. 2006)
`
`Ex. 1035A Edvinsson and Hargreaves, The Headaches 289-299 (3rd
`ed. 2006)
`
`Ex. 1036
`
`Reserved
`
`Ex. 1037
`
`Reserved
`
`Ex. 1038 Mason et al., “Release of the Predicted Calcitonin Gene-
`Related Peptide from Cultured Rat Trigeminal Ganglion
`Cells,” Nature (1984) 308: 653-655
`
`Ex. 1038A Mason et al., “Release of the Predicted Calcitonin Gene-
`Related Peptide from Cultured Rat Trigeminal Ganglion
`Cells,” Nature (1984) 308: 653-655
`
`Ex. 1039
`
`Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Ex. 1039A Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Ex. 1040
`
`Arulmozhi et al., “Migraine: Current Concepts and
`Emerging Therapies,” Vascular Pharmacol. (2005) 43:
`176-187
`
`4
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1040A Arulmozhi et al., “Migraine: Current Concepts and
`Emerging Therapies,” Vascular Pharmacol. (2005) 43:
`176-187
`
`Ex. 1041
`
`Durham, “CGRP-Receptor Antagonists — A Fresh
`Approach to Migraine Therapy?” N. Engl. Med. (2004)
`350(11): 1073-1075
`
`Ex. 1041A Durham, “CGRP-Receptor Antagonists — A Fresh
`Approach to Migraine Therapy?” N. Engl. Med. (2004)
`350(11): 1073-1075
`
`Ex. 1042
`
`Ex. 1042A
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of
`BIBN 4096 BS, the First Selective Small Molecule
`Calcitonin Gene-related Peptide Receptor Antagonist,
`Following Single Intravenous Administration in Healthy
`Volunteers,” Cephalalgia (2004) 24: 645-656
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of
`BIBN 4096 BS, the First Selective Small Molecule
`Calcitonin Gene-related Peptide Receptor Antagonist,
`Following Single Intravenous Administration in Healthy
`Volunteers,” Cephalalgia (2004) 24: 645-656
`
`Ex. 1043
`
`Goadsby et al., “Vasoactive Peptide Release in the
`Extracerebral Circulation of Humans During Migraine
`Headache,” Annals of Neurology (1990) 28(2): 183-187
`
`Ex. 1043A Goadsby et al., “Vasoactive Peptide Release in the
`Extracerebral Circulation of Humans During Migraine
`Headache,” Annals of Neurology (1990) 28(2): 183-187
`
`Ex. 1044
`
`Goadsby and Edvinsson, “The Trigeminovascular System
`and Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals
`of Neurology (1993) 33(1): 48-56
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`5
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1044A Goadsby and Edvinsson, “The Trigeminovascular System
`and Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals
`of Neurology (1993) 33(1): 48-56
`
`Ex. 1045
`
`Ex. 1045A
`
`Ex. 1046
`
`Juhasz et al., “NO-induced Migraine Attack: Strong
`Increase in Plasma Calcitonin Gene-Related Peptide
`(CGRP) Concentration and Negative Correlation with
`Platelet Serotonin Release,” Pain (2003) 106: 461-470
`
`Juhasz et al., “NO-induced Migraine Attack: Strong
`Increase in Plasma Calcitonin Gene-Related Peptide
`(CGRP) Concentration and Negative Correlation with
`Platelet Serotonin Release,” Pain (2003) 106: 461-470
`
`Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache:
`Neuropeptide Changes and Effects of Acute Attacks
`Therapies,” Brain (1994) 117: 427-434
`
`Ex. 1046A Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache:
`Neuropeptide Changes and Effects of Acute Attacks
`Therapies,” Brain (1994) 117: 427-434
`
`Ex. 1047
`
`Lassen et al., “CGRP May Play a Causative Role in
`Migraine,” Cephalagia (2002) 22: 54-61
`
`Ex. 1047A Lassen et al., “CGRP May Play a Causative Role in
`Migraine,” Cephalagia (2002) 22: 54-61
`
`Ex. 1048
`
`Louis et al., “Antibodies to Calcitonin-Gene Related
`Peptide Reduce Inflammation Induced by Topical Mustard
`Oil But Not that Due to Carrageenin in the Rat,”
`Neuroscience Letters (1989) 102: 257-260
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`6
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1048A Louis et al., “Antibodies to Calcitonin-Gene Related
`Peptide Reduce Inflammation Induced by Topical Mustard
`Oil But Not that Due to Carrageenin in the Rat,”
`Neuroscience Letters (1989) 102: 257-260
`
`Ex. 1049
`
`Dockray et al., “Immunoneutralization Studies with
`Calcitonin Gene-Related Peptide,” Annals of N.Y. Acad.
`Scis. (1992) 258-267
`
`Ex. 1049A Dockray et al., “Immunoneutralization Studies with
`Calcitonin Gene-Related Peptide,” Annals of N.Y. Acad.
`Scis. (1992) 258-267
`
`Ex. 1050
`
`Louis et al., “The Role of Substance P and Calcitonin
`Gene-Related Peptide in Neurogenic Plasma Extravasation
`and Vasodilation in the Rat,” Neuroscience (1989) 32(3):
`581-586
`
`Ex. 1050A Louis et al., “The Role of Substance P and Calcitonin
`Gene-Related Peptide in Neurogenic Plasma Extravasation
`and Vasodilation in the Rat,” Neuroscience (1989) 32(3):
`581-586
`
`Ex. 1051
`
`Ex. 1052
`
`Sigma-Aldrich, Biochemicals & Reagents for Life Science
`Research 350-352 (2004)
`
`Escott and Brain, “Effect of a Calcitonin Gene-Related
`Peptide Antagonist (CGRP8-37) on Skin Vasodilatation and
`Oedema Induced by Stimulation of the Rat Saphenous
`Nerve,” Br. J. Pharmacol. (1993) 110: 772-776
`
`Ex. 1052A Escott and Brain, “Effect of a Calcitonin Gene-Related
`Peptide Antagonist (CGRP8-37) on Skin Vasodilatation and
`Oedema Induced by Stimulation of the Rat Saphenous
`Nerve,” Br. J. Pharmacol. (1993) 110: 772-776
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`X
`
`7
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1053
`
`Reserved
`
`Ex. 1054
`
`Reserved
`
`Ex. 1055
`
`Andrew et al., “Monoclonal Antibodies Distinguishing α
`and β Forms of Calcitonin Gene-Related Peptide,” J.
`Immunol. Methods (1990) 154: 87-94
`
`Ex. 1055A Andrew et al., “Monoclonal Antibodies Distinguishing α
`and β Forms of Calcitonin Gene-Related Peptide,” J.
`Immunol. Methods (1990) 154: 87-94
`
`Ex. 1056
`
`Reichert et al., “Monoclonal Antibody Successes in the
`Clinic,” Nature Biotechnol. (2005) 23: 1073-1078
`
`Ex. 1056A Reichert et al., “Monoclonal Antibody Successes in the
`Clinic,” Nature Biotechnol. (2005) 23: 1073-1078
`
`Ex. 1057
`
`Projan et al., “Small Molecules for Small Minds? The Case
`for Biologic Pharmaceuticals,” Expert Opin. Biol. Ther.
`(2004) 4: 1345-1350
`
`Ex. 1057A Projan et al., “Small Molecules for Small Minds? The Case
`for Biologic Pharmaceuticals,” Expert Opin. Biol. Ther.
`(2004) 4: 1345-1350
`
`Ex. 1058
`
`Janeway et al., Immunobiology 93-122 (5th ed. 2001)
`
`Ex. 1059
`
`Janeway et al., Immunobiology 123-154 (5th ed. 2001)
`
`Ex. 1060
`
`Janeway et al., Immunobiology 341-380 (5th ed. 2001)
`
`Ex. 1061
`
`Van Valen et al., “Calcitonin Gene-Related Peptide
`(CGRP) Receptors are Linked to Cyclic Adenosine
`Monophosphate Production in SK-N-MC Human
`Neuroblastoma Cells,” Neuroscience Letters (1990) 119:
`195-198
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`8
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1061A Van Valen et al., “Calcitonin Gene-Related Peptide
`(CGRP) Receptors are Linked to Cyclic Adenosine
`Monophosphate Production in SK-N-MC Human
`Neuroblastoma Cells,” Neuroscience Letters (1990) 119:
`195-198
`
`Ex. 1062
`
`Kipriyanov and Le Gall, “Generation and Production of
`Engineered Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Ex. 1062A Kipriyanov and Le Gall, “Generation and Production of
`Engineered Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Ex. 1063
`
`Elgert, Immunology: Understanding the Immune System
`58-78 (1st ed. 1996)
`
`Ex. 1064 Wright and Morrison, “Effect of Glycosylation on
`Antibody Function: Implications for Genetic Engineering,”
`Trends Biotechnol. (1997) 15: 26-32
`
`Ex. 1064A Wright and Morrison, “Effect of Glycosylation on
`Antibody Function: Implications for Genetic Engineering,”
`Trends Biotechnol. (1997) 15: 26-32
`
`Ex. 1065
`
`Brüggemann et al., “Comparison of the Effector Functions
`of Human Immunoglobulins Using a Matched Set of
`Chimeric Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Ex. 1065A Brüggemann et al., “Comparison of the Effector Functions
`of Human Immunoglobulins Using a Matched Set of
`Chimeric Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Ex. 1066
`
`Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-
`736
`
`X
`
`
`
`X
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`9
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1066A Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-
`736
`
`Ex. 1067
`
`Tao and Morrison, “Studies of Aglycosylated Chimeric
`Mouse-Human IgG: Role of Carbohydrate in the Structure
`and Effector Functions Mediated by the Human IgG
`Constant Region,” J. Immunol. (1989) 143: 2595-2601
`
`Ex. 1067A Tao and Morrison, “Studies of Aglycosylated Chimeric
`Mouse-Human IgG: Role of Carbohydrate in the Structure
`and Effector Functions Mediated by the Human IgG
`Constant Region,” J. Immunol. (1989) 143: 2595-2601
`
`Ex. 1068 Maynard and Georgiou, “Antibody Engineering,” Annu.
`Rev. Biomed. Eng. (2000) 2: 339-376
`
`Ex. 1068A Maynard and Georgiou, “Antibody Engineering,” Annu.
`Rev. Biomed. Eng. (2000) 2: 339-376
`
`Ex. 1069
`
`Chester and Hawkins, “Clinical Issues in Antibody
`Design,” Trends Biotechnol. (1995) 13: 294-300
`
`Ex. 1069A Chester and Hawkins, “Clinical Issues in Antibody
`Design,” Trends Biotechnol. (1995) 13: 294-300
`
`Ex. 1070
`
`Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Ex. 1070A Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Ex. 1071
`
`Gavilondo and Larrick, “Antibody Engineering at the
`Millennium,” BioTechniques (2000) 29: 128-145
`
`Ex. 1071A Gavilondo and Larrick, “Antibody Engineering at the
`Millennium,” BioTechniques (2000) 29: 128-145
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`10
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1072
`
`Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Ex. 1072A Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Ex. 1073
`
`Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Ex. 1073A Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Ex. 1074
`
`Kettleborough et al., “Humanization of a Mouse
`Monoclonal Antibody by CDR-Grafting: The Importance
`of Framework Residues on Loop Conformation,” Protein
`Eng. (1991) 4: 773-783
`
`Ex. 1074A Kettleborough et al., “Humanization of a Mouse
`Monoclonal Antibody by CDR-Grafting: The Importance
`of Framework Residues on Loop Conformation,” Protein
`Eng. (1991) 4: 773-783
`
`Ex. 1075
`
`Queen et al., “A Humanized Antibody that Binds to the
`Interleukin 2 Receptor,” Proc. Natl. Acad. Sci. USA (1989)
`86: 10029-10033
`
`Ex. 1075A Queen et al., “A Humanized Antibody that Binds to the
`Interleukin 2 Receptor,” Proc. Natl. Acad. Sci. USA (1989)
`86: 10029-10033
`
`Ex. 1076
`
`Friend et al., “Phase I Study of an Engineered
`Aglycosylated Humanized CD3 Antibody in Renal
`Transplant Rejection,” Transplantation (1999) 68: 1632-
`1637
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`11
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1076A Friend et al., “Phase I Study of an Engineered
`Aglycosylated Humanized CD3 Antibody in Renal
`Transplant Rejection,” Transplantation (1999) 68: 1632-
`1637
`
`Ex. 1077
`
`Brekke and Sandlie, “Therapeutic Antibodies for Human
`Diseases at the Dawn of the Twenty-First Century,” Nature
`Revs. Drug Discov. (2003) 2: 52-62
`
`Ex. 1077A Brekke and Sandlie, “Therapeutic Antibodies for Human
`Diseases at the Dawn of the Twenty-First Century,” Nature
`Revs. Drug Discov. (2003) 2: 52-62
`
`Ex. 1078
`
`Reserved
`
`Ex. 1079
`
`Huse et al., International Publication No. WO 2001/27160
`
`Ex. 1080
`
`Reserved
`
`Ex. 1081
`
`Reserved
`
`Ex. 1082
`
`Vater et al., “Short Bioactive Spiegelmers to Migraine-
`Associated Calcitonin Gene-Related Peptide Rapidly
`Identified by a Novel Approach: Tailored-SELEX,”
`Nucleic Acids Res. (2003) 31: 1-7
`
`Ex. 1083
`
`Reserved
`
`Ex. 1084
`
`Reserved
`
`Ex. 1085
`
`Reserved
`
`Ex. 1086
`
`Reserved
`
`Ex. 1087
`
`Johnstone et al., “The Effect of Temperature on the
`Binding Kinetics and Equilibrium Constants of Monoclonal
`
`12
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Antibodies to Cell Surface Antigens,” Mol. Immunol.
`(1990) 27: 327-333
`
`Ex. 1088
`
`Reserved
`
`Ex. 1089
`
`Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`Ex. 1089A Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`Ex. 1090
`
`Petersen et al., “Inhibitory Effect of BIBN4096BS on
`Cephalic Vasodilation Induced by CGRP or Transcranial
`Electrical Stimulation in the Rat,” Br. J. Pharm. (2004)
`143: 697-704
`
`Ex. 1090A Petersen et al., “Inhibitory Effect of BIBN4096BS on
`Cephalic Vasodilation Induced by CGRP or Transcranial
`Electrical Stimulation in the Rat,” Br. J. Pharm. (2004)
`143: 697-704
`
`Ex. 1091
`
`Purves et al., Neuroscience 763-773 (3rd ed. 2004)
`
`Ex. 1092
`
`Reserved
`
`Ex. 1093
`
`Reserved
`
`Ex. 1094
`
`Reserved
`
`Ex. 1095
`
`Conner et al., “Interaction of Calcitonin-Gene-Related
`Peptide with Its Receptors,” Biochemistry Society
`Transactions (2002) 30(4): 451-455
`
`Ex. 1095A Conner et al., “Interaction of Calcitonin-Gene-Related
`Peptide with Its Receptors,” Biochemistry Society
`Transactions (2002) 30(4): 451-455
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`X
`
`13
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1096 Wimalawansa, “Calcitonin Gene-Related Peptide and Its
`Receptors: Molecular Genetics, Physiology,
`Pathophysiology, and Therapeutic Potentials,” Endocrine
`Revs. (1996) 17(5): 533-585
`
`Ex. 1097 Williamson et al., “Intravital Microscope Studies on the
`Effects of Neurokinin Agonists and Calcitonin Gene-
`Related Peptide on Dural Vessel Diameter in the
`Anaesthetized Rat,” Cephalalgia (1997) 17: 518-524
`
`Ex. 1098
`
`Hong et al., “Pharmacological Coupling and Functional
`Role for CGRP Receptors in the Vasodilation of Rat Pial
`Arterioles,” Am. J. Physiol. (1996) 270: H317-H323
`
`Ex. 1099
`
`Reserved
`
`Ex. 1100
`
`Reserved
`
`Ex. 1101
`
`Jones et al., “Replacing the Complementarity-Determining
`Regions in a Human Antibody with Those from a Mouse,”
`Nature (1986) 321: 522-525
`
`Ex. 1101A
`
`Jones et al., “Replacing the Complementarity-Determining
`Regions in a Human Antibody with Those from a Mouse,”
`Nature (1986) 321: 522-525
`
`Ex. 1102
`
`Reserved
`
`Ex. 1103
`
`Ex. 1104
`
`Ex. 1105
`
`Tysabri® Letter from the Food and Drug Administration
`(2004)
`
`Pollack, “F.D.A. Approves a Multiple Sclerosis Drug,”
`New York Times (November 24, 2004)
`
`Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,”
`Am. J. Gastroenterol (2003) 98: 2372-2382
`
`
`
`
`
`
`
`
`
`
`
`
`
`X
`
`
`
`
`
`
`
`
`
`14
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1105A Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,”
`Am. J. Gastroenterol (2003) 98: 2372-2382
`
`Ex. 1106
`
`Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M.
`(eds) Tumor Targeting in Cancer Therapy. Cancer Drug
`Discovery and Development. Humana Press, Totowa, NJ.
`
`Ex. 1106A Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M.
`(eds) Tumor Targeting in Cancer Therapy. Cancer Drug
`Discovery and Development. Humana Press, Totowa, NJ.
`
`Ex. 1107
`
`Reserved
`
`Ex. 1108
`
`Reserved
`
`Ex. 1109
`
`Reserved
`
`Ex. 1110
`
`Tsurushita et al., “Design of Humanized Antibodies: From
`anti-Tac to Zenapax,” Methods (2005) 36: 69-83
`
`Ex. 1111
`
`Reserved
`
`Ex. 1112
`
`Reserved
`
`Ex. 1113
`
`Reserved
`
`Ex. 1114
`
`Reserved
`
`Ex. 1115
`
`Reserved
`
`Ex. 1116
`
`Reserved
`
`Ex. 1117
`
`Reserved
`
`Ex. 1118
`
`Reserved
`
`Ex. 1119
`
`Reserved
`
`15
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1120
`
`Reserved
`
`Ex. 1121
`
`Reserved
`
`Ex. 1122
`
`Reserved
`
`Ex. 1123
`
`Reserved
`
`Ex. 1124
`
`Reserved
`
`Ex. 1125
`
`Reserved
`
`Ex. 1126
`
`Reserved
`
`Ex. 1127
`
`Lilly’s U.S. Provisional Application No. 60/753,004
`
`Ex. 1128
`
`U.S. Provisional Application No. 60/711,950
`
`Ex. 1129
`
`Reserved
`
`Ex. 1130
`
`Janeway et al., Immunobiology 626-627 (5th ed. 2001)
`
`Ex. 1131
`
`Reserved
`
`Ex. 1132
`
`Reserved
`
`Ex. 1133
`
`Reserved
`
`Ex. 1134
`
`Reserved
`
`Ex. 1135
`
`Reserved
`
`Ex. 1136
`
`September 5, 2013 Teva’s Response to Office Action (U.S.
`Patent No. 8,597,649 prosecution history)
`
`Ex. 1137
`
`Reserved
`
`Ex. 1138
`
`Reserved
`
`16
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1139
`
`Reserved
`
`Ex. 1140
`
`Reserved
`
`Ex. 1141
`
`Reserved
`
`Ex. 1142
`
`Reserved
`
`Ex. 1143
`
`Reserved
`
`Ex. 1144
`
`Reserved
`
`Ex. 1145
`
`Reserved
`
`Ex. 1146
`
`Reserved
`
`Ex. 1147
`
`Reserved
`
`Ex. 1148
`
`Reserved
`
`Ex. 1149
`
`Reserved
`
`Ex. 1150
`
`Reserved
`
`Ex. 1151
`
`Reserved
`
`Ex. 1152
`
`Reserved
`
`Ex. 1153
`
`Reserved
`
`Ex. 1154
`
`Reserved
`
`Ex. 1155
`
`Reserved
`
`Ex. 1156
`
`Reserved
`
`Ex. 1157
`
`Reserved
`
`Ex. 1158
`
`Reserved
`
`17
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1159
`
`Reserved
`
`Ex. 1160
`
`Reserved
`
`Ex. 1161
`
`Reserved
`
`Ex. 1162
`
`Reserved
`
`Ex. 1163
`
`Reserved
`
`Ex. 1164
`
`Reserved
`
`Ex. 1165
`
`Reserved
`
`Ex. 1166
`
`Reserved
`
`Ex. 1167
`
`Reserved
`
`Ex. 1168
`
`Reserved
`
`Ex. 1169
`
`Reserved
`
`Ex. 1170
`
`Reserved
`
`Ex. 1171
`
`Reserved
`
`Ex. 1172
`
`Reserved
`
`Ex. 1173
`
`Reserved
`
`Ex. 1174
`
`Reserved
`
`Ex. 1175
`
`Reserved
`
`Ex. 1176
`
`Reserved
`
`Ex. 1177
`
`Reserved
`
`Ex. 1178
`
`Reserved
`
`18
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1179
`
`Reserved
`
`Ex. 1180
`
`Reserved
`
`Ex. 1181
`
`Reserved
`
`Ex. 1182
`
`Reserved
`
`Ex. 1183
`
`Reserved
`
`Ex. 1184
`
`Reserved
`
`Ex. 1185
`
`Reserved
`
`Ex. 1186 May 5, 2017 Application Data Sheet (U.S. Patent No.
`9,890,210 prosecution history)
`
`Ex. 1187
`
`Ex. 1188
`
`Ex. 1189
`
`June 23, 2017 Office Action (U.S. Patent No. 9,890,210
`prosecution history)
`
`August 23, 2017 Teva’s Response to Office Action (U.S.
`Patent No. 9,890,210 prosecution history)
`
`August 23, 2017 Terminal Disclaimers (U.S. Patent No.
`9,890,210 prosecution history)
`
`Ex. 1190 May 26, 2017 Information Disclosure Statement (U.S.
`Patent No. 9,890,210 prosecution history)
`
`Ex. 1191
`
`October 27, 2017 Information Disclosure Statement (U.S.
`Patent No. 9,890,210 prosecution history)
`
`Ex. 1192
`
`Reserved
`
`Ex. 1193
`
`Reserved
`
`Ex. 1194
`
`Reserved
`
`19
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1195
`
`Reserved
`
`Ex. 1196
`
`Reserved
`
`Ex. 1197
`
`Reserved
`
`Ex. 1198
`
`Reserved
`
`Ex. 1199
`
`Reserved
`
`Ex. 1200
`
`Reserved
`
`Ex. 1201
`
`Reserved
`
`Ex. 1202
`
`Reserved
`
`Ex. 1203
`
`Reserved
`
`Ex. 1204
`
`Reserved
`
`Ex. 1205
`
`Reserved
`
`Ex. 1206
`
`Reserved
`
`Ex. 1207
`
`Reserved
`
`Ex. 1208
`
`Reserved
`
`Ex. 1209
`
`Reserved
`
`Ex. 1210
`
`Reserved
`
`Ex. 1211
`
`Reserved
`
`Ex. 1212
`
`Reserved
`
`Ex. 1213
`
`Reserved
`
`Ex. 1214
`
`Reserved
`
`20
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1215
`
`Reserved
`
`Ex. 1216
`
`Reserved
`
`Ex. 1217
`
`Reserved
`
`Ex. 1218
`
`Reserved
`
`Ex. 1219
`
`Reserved
`
`Ex. 1220
`
`Reserved
`
`Ex. 1221
`
`Reserved
`
`Ex. 1222
`
`Reserved
`
`Ex. 1223
`
`Reserved
`
`Ex. 1224
`
`Reserved
`
`Ex. 1225
`
`Reserved
`
`Ex. 1226
`
`Reserved
`
`Ex. 1227
`
`Reserved
`
`Ex. 1228
`
`Reserved
`
`Ex. 1229
`
`Reserved
`
`Ex. 1230
`
`Reserved
`
`Ex. 1231
`
`Reserved
`
`Ex. 1232
`
`Reserved
`
`Ex. 1233
`
`Reserved
`
`Ex. 1234
`
`Reserved
`
`21
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1235
`
`Reserved
`
`Ex. 1236
`
`Reserved
`
`Ex. 1237
`
`Reserved
`
`Ex. 1238
`
`Reserved
`
`Ex. 1239
`
`Reserved
`
`Ex. 1240 Messlinger et al., “Inhibition of Neurogenic Blood Flow
`Increases in the Rat Cranial Dura Mater by a CGRP-
`Binding Spiegelmer,” Cephalalgia (2005) 25: 923 (F022)
`
`Ex. 1241
`
`Reserved
`
`Ex. 1242
`
`Reserved
`
`Ex. 1243
`
`Reserved
`
`Ex. 1244
`
`Reserved
`
`Ex. 1245
`
`Reserved
`
`Ex. 1246
`
`Reserved
`
`Ex. 1247
`
`Covell et al., “Pharmacokinetics of Monoclonal
`Immunoglobulin G1, F(ab’)2, and Fab’ in Mice,” Cancer
`Res. (1986) 46: 3969-3978
`
`Ex. 1248
`
`Reserved
`
`Ex. 1249
`
`Reserved
`
`Ex. 1250
`
`Reserved
`
`Ex. 1251
`
`Reserved
`
`22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1252
`
`Reserved
`
`Ex. 1253
`
`Reserved
`
`Ex. 1254
`
`Reserved
`
`Ex. 1255
`
`Reserved
`
`Ex. 1256
`
`Reserved
`
`Ex. 1257
`
`Reserved
`
`Ex. 1258
`
`Reserved
`
`Ex. 1259
`
`Reserved
`
`Ex. 1260
`
`Reserved
`
`Ex. 1261
`
`Clayton et al., U.S. Patent No. 6,861,441
`
`Ex. 1262
`
`Foord et al., U.S. Patent Publication No. US 2002/0137892
`
`Ex. 1263
`
`Ex. 1264
`
`Arulmani et al., “Effects of the Calcitonin Gene-Related
`Peptide (CGRP) Receptor Antagonist BIBN2096BS on α-
`CGRP-Induced Regional Haemodynamic Changes in
`Anaesthetized Rats,” Pharmacology & Toxicology (2004)
`94: 291-297
`
`Bernardis et al., “Human Domain Antibodies Against
`Virulence Traits of Candida Albicans Inhibit Fungus
`Adherence to Vaginal Epithelium and Protect Against
`Experimental Vaginal Candidiasis,” J. Infectious Diseases
`(2007) 195: 149-157
`
`Ex. 1265
`
`Ignatovich et al., “The Creation of Diversity in the Human
`Immunoglobulin Vλ Repertoire,” J. Mol Biol. (1997) 268:
`69-77
`
`23
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1266
`
`Ex. 1267
`
`Ex. 1268
`
`Tomlinson, “Next-Generation Protein Drugs,” Nature
`Biotechnology (2004) 22(5): 521-522
`
`Enever et al., “Engineering High Affinity Superantigens by
`Phage Display,” J. Mol Biol. (2005) 347: 107-120
`
`Holt et al., “Domain Antibodies: Proteins for Therapy,”
`TRENDS in Biotechnology (2003) 21(11): 484-490
`
`Ex. 1269 Miyamoto et al., “Heparin-Binding EGF-Like Growth
`Factor Is a Promising Target for Ovarian Cancer Therapy,”
`Cancer Research (2004) 64: 5720-5727
`
`Ex. 1270
`
`Challenged Patents and Claims Table
`
`Ex. 1271
`
`Glaxo Grp. Ltd. v. Genentech Inc., EWHC 1416, Chancery
`Division (Patents Court) (2007)
`
`Ex. 1272
`
`Bigal, U.S. Patent Publication No. 2017/0088612
`
`Ex. 1273
`
`Poulsen et al., U.S. Patent No. 9,328,167
`
`Ex. 1274
`
`Poulsen et al., U.S. Patent No. 8,293,239
`
`Ex. 1275
`
`Corradini et al., U.S. Patent No. 8,298,536
`
`Ex. 1276
`
`Pios et al., U.S. Patent No. 8,623,366
`
`Ex. 1277
`
`Bigal et al., U.S. Patent No. 9,896,502
`
`Ex. 1278
`
`Bigal et al., U.S. Patent Publication No. 2018/0127490
`
`Ex. 1279
`
`Zeller et al., U.S. Patent No. 9,328,168
`
`Ex. 1280
`
`Reserved
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`24
`
`
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ferrari and Saxena, “Clinical Effects and Mechanism of
`Action of Sumatriptan in Migraine,” Clinical Neurology &
`Neurosurgery (1992) 94 (Supp.): 573-577
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Ex. 1281
`
`Ex. 1282
`
`Physicians’ Desk Reference, Imitrex® (2004)
`
`Ex. 1283
`
`Källner et al., “Calcitonin Gene-Related Peptide in
`Myocardial Ischaemia and Reperfusion in the Pig,”
`Cardiovascular Research (1998) 38: 493-499
`
`Ex. 1284 Wu et al., “Effects of Calcitonin Gene-Related Peptide and
`BIBN4096BS on Myocardial Ischemia in Anesthetized
`Rats,” Acta Pharmacol. Sin. (2001) 22(7): 588-594
`
`Ex. 1285
`
`Ex. 1286
`
`Ex. 1287
`
`Ex. 1288
`
`Shen et al., “Effects of Inhibition of α-CGRP Receptors on
`Cardiac and Peripheral Vascular Dynamics in Conscious
`Dogs with Chronic Heart Failure,” J. Cardiovasc.
`Pharmacol. (2003) 42(5): 656-661
`
`Hargreaves, Chapter 9: Triptans to Calcitonin Gene-
`Related Peptide Modulators – Small molecules to
`Antibodies – the Evolution of a New Migraine Drug Class,
`Neurological Basis of Migraine 157-174 (1st ed. 2017)
`
`Tan, “Application of Monoclonal Antibodies to the
`Investigation of the Role of Calcitonin Gene-Related
`Peptide as a Vasodilatory Neurotransmitter,” Dissertation
`Submitted to the University of Cambridge (1994)
`
`Lu et al., “Mice Lacking α-Calcitonin Gene-Related
`Peptide Exhibit Normal Cardiovascular Regulation and
`Neuromuscular Development,” Molecular & Cellular
`Neuroscience (1999) 14: 99-120
`
`Ex. 1289
`
`Reserved
`
`25
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1290
`
`Ex. 1291
`
`Ex. 1292
`
`Ex. 1293
`
`Ex. 1294
`
`Ex. 1295
`
`Ex. 1296
`
`Ex. 1297
`
`Stam et al., “Migraine: New Treatment Options from
`Molecular Biology,” Expert Rev. Neurotherapeutics (2005)
`5(5): 653-661
`
`Saper et al., “Intranasal Civamide for the Treatment of
`Episodic Cluster Headaches,” Arch Neurol. (2002) 59: 990-
`994
`
`Diamond et al., “Intranasal Civamide for the Acute
`Treatment of Migraine Headaches,” Cephalalgia (2000)
`20: 596-602
`
`Rapoport et al., “Which Triptan for Which Patient?,”
`Neurol. Sci. (2006) 27: S123-S129
`
`Rapoport et al., “Naratriptan in the Preventive Treatment of
`Refractory Chronic Migraine: A Review of 27 Cases,”
`Headache (2003) 43: 482-489
`
`Sheftell et al., “Naratriptan in the Preventive Treatment of
`Refractory Transformed Migraine: A Prospective Pilot
`Study,” Headache (2005) 45: 1400-1406
`
`Ho et al., “Randomized Controlled Trial of an Oral CGRP
`Receptor Antagonist, MK-0974, in Acute Treatment of
`Migraine,” Neurology (2008) 70: 1304-1312
`
`Rapoport and Bigal, “Migraine Preventive Therapy:
`Current and Emerging Treatment Options,” Neurol. Sci.
`(2005) 26: S111-S120
`
`Ex. 1298
`
`Reserved
`
`Ex. 1299
`
`Reserved
`
`Ex. 1300
`
`Deposition Transcript of Steven M. Foord, Ph.D.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`26
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1301
`
`Deposition Transcript of Ian M. Tomlinson, M.A., Ph.D.
`
`Ex. 1302
`
`Deposition Transcript of Robert D. Stoner, Ph.D.
`
`Ex. 1303
`
`Deposition Transcript of Michel D. Ferrari, M.D., Ph.D.
`
`Ex. 1304
`
`Deposition Transcript of Alan M. Rapoport, M.D.
`
`Ex. 1305
`
`Reserved
`
`Ex. 1306
`
`Reserved
`
`Ex. 1307
`
`Reserved
`
`Ex. 1308
`
`Ex. 1309
`
`Ferrari et al., “Oral Triptans (Serotonin 5-HT18/10 Agonists)
`in Acute Migraine Treatment: A Meta-Analysis of 53
`Trials,” (2001) Lancet 358: 1668-1675
`
`Pendergrast et al., “Nucleic Acid Aptamers for Target
`Validation and Therapeutic Applications,” J. Biomolecular
`Techniques (2005) 16: 224-234
`
`Ex. 1310
`
`Reserved
`
`Ex. 1311
`
`Evers and Mylecharane, The Headaches 553-566 (3rd ed.
`2006)
`
`Ex. 1312
`
`Reserved
`
`Ex. 1313
`
`Ho et al., “Efficacy and Tolerability of MK-0974
`(Telcagepant), A New Oral Antagonist of Calcitonin Gene-
`Related Peptide Receptor, Compared with Zolmitriptan for
`Acute Migraine: A Randomised, Placebo-Controlled,
`Parallel-Treatment Trial,” Lancet (2008) 372: 2115-2123
`
`Ex. 1314
`
`Silberstein et al., “The International Classification of
`Headache Disorders, 2nd Edition (ICHD-II)—Revision of
`
`27
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01425
`Patent No. 9,890,210
`
`Served
`Not
`Filed
`
`Ex. 1315
`
`Ex. 1316
`
`Ex. 1317
`
`Ex. 1318
`
`Criteria for 8.2 Medication-Overuse Headache,”
`Cephalalgia (2005) 25: 460-465
`
`Petitti et al., “Incidence of Stroke and Myocardial
`Infarction in Women of Reproductive Age,” Stroke (1997)
`28: 280-283
`
`Tfelt-Hansen
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
